Drugdocs | Viltepso

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Viltepso

Chemical Name	viltolarsen
Dosage Form	Injection (intravenous; 250 mg/5 mL, 50 mg/mL)
Drug Class	Oligonucleotides
System	Musculoskeletal
Company	NS Pharma Inc.
Approval Year	2020

Indication

For the treatment of Duchenne muscular dystrophy (DMD) in patients amenable to exon 53 skipping

Last updated on 12/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
VILTEPSO (viltolarsen) Prescribing Information.	2020	NS Pharma, Inc. Paramus, NJ

Document Title	Year	Source
A phase 3 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of viltolarsen in ambulant boys with Duchenne muscular dystrophy (DMD).	2020	NS Pharma, Inc.